◈ Nootpedia
Compact view
Research pass: medium Supplement · Powder SKIP-FOR-NOW MEDIUM

5-HTP

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

For Dylan, L-tryptophan is the strictly better choice — it preserves the TPH/IDO regulatory bottleneck that quality-controls serotonin synthesis, while 5-HTP overrides it and produces serotonin disproportionately in the periphery (GI, cardiovascular). 5-HTP's only real advantage is faster onset, and that gain is modest. Would shift to OPTIONAL-ADD only in a context where TPH/IDO is genuinely blunted (e.g., chronic high-CRP inflammation diverting tryptophan to kynurenines, or documented TPH2 loss-of-function variant) and a clinician is using 5-HTP tactically rather than chronically.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    (MEDIUM confidence). Tryptophan dominates on every axis except onset speed. The dopamine-depletion concern is non-trivial in a profile where cognitive output is the top priority. Peripheral 5-HT side effects + theoretical chronic-use valve concern + EMS-legacy sourcing risk all argue against chronic daily use when a strictly safer alternative exists.

  • 30-50, executive maintenance
    SKIP-FOR-NOW

    Same logic. Low-dose intermittent use for occasional sleep difficulty is defensible; daily use isn't.

  • 50+, mild cognitive decline
    SKIP

    / use cautiously. Aging cardiovascular tissue is more vulnerable to 5-HT2B-mediated remodeling. Tryptophan + low-dose melatonin is preferred.

  • Anxiety-prone
    SKIP

    Variable response (calming or jittering); tryptophan and L-theanine are cleaner first-line picks.

  • High athletic load, tested status
    SKIP

    for daily use. Not WADA-banned. But athletic populations have elevated baseline inflammation that already shifts tryptophan toward kynurenines — adding 5-HTP doesn't fix the inflammation, and the AAAD competition can subtly ding dopamine-driven motivation/training output.

  • Sleep-disordered
    OPTIONAL-ADD

    with caveats if tryptophan has been trialed adequately and failed. Short-term (2-4 week) low-dose (50-100 mg) trial is reasonable in this scenario. Daridorexant or melatonin (low-dose) are cleaner escalations.

  • Recovery-focused (post-injury/illness)
    SKIP

    Inflammation drives IDO/kynurenine — fix inflammation, not bypass it.

  • Strength/anabolic-focused
    SKIP

    Dopamine-side AAAD competition is mildly contraindicated for motivation/training output.

▸ Subjective experience (deep)

Per user reports (Reddit, Drugs.com comments, Erowid, Examine.com syntheses):

  • Onset: 30-60 min after dose. Faster than tryptophan because TPH step is skipped.
  • Peak: 60-120 min. Most pronounced effects: drowsiness (dose-dependent), warm/relaxed feeling, sometimes a faintly "buzzy" or "pressure-in-the-head" sensation that some users dislike.
  • Sleep: Reasonably effective for sleep onset at 100-200 mg pre-bed. Many report vivid, intense dreams within the first few nights — sometimes pleasant, sometimes nightmare-flavored. REM rebound is real.
  • GI: Nausea is the #1 complaint. Often dose-related, often worst on empty stomach (paradoxically — opposite of tryptophan, where empty stomach is preferred for LNAA reasons). Some users get loose stool / mild cramping. Enteric-coated formulations exist specifically for this reason.
  • Mood: Some users report quick subjective lift; others report emotional flatness, apathy, or jitteriness/anxiety — likely the dopamine-depletion signature from AAAD substrate competition.
  • Headache: Modestly common (~5-15% of users), especially at higher doses (200 mg+).
  • Morning: Generally clear, but occasional reports of grogginess if dosed late or at >200 mg.
  • Tolerance/wear-off: Many users report initial benefit fades over 2-4 weeks of daily use, often paired with worsening mood or "feeling off." Consistent with the dopamine depletion thesis: as 5-HTP saturates AAAD, less L-DOPA is decarboxylated, dopamine drifts down, mood/motivation suffer.

Variability: Strong. Some users tolerate 100 mg with clean sleep benefit and no GI; others get nausea at 50 mg. 5-HTTLPR genotype, baseline serotonergic tone, B6 status, and gut microbiome (TPH1 in enterochromaffin cells is microbiome-modulated) all plausibly contribute.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Moderate, often via dopamine depletion rather than receptor downregulation. Unlike tryptophan (which is restoring substrate to a regulated pathway and shows essentially no tolerance), 5-HTP saturates AAAD and shifts the precursor balance toward serotonin and away from dopamine. Many users describe "5-HTP poop-out" after 2-6 weeks of daily use.
  • Recommended cycle: If used at all, 5-7 days on / 2-3 days off, or 2-3 weeks on / 1 week off. Some practitioners co-prescribe L-tyrosine to support dopamine synthesis through the parallel AAAD branch (questionable mechanism — both substrates compete for the same enzyme — but rationale exists in the integrative-medicine literature).
  • Reset protocol: 2-4 weeks off restores baseline.
▸ Stacking deep dive

Synergistic with

  • vitamin-b6 (P5P) — required AAAD cofactor. Without adequate B6, 5-HTP conversion stalls. 25-50 mg P5P alongside 5-HTP is the standard pairing.
  • carbidopa or benserazide (Rx, peripheral AAAD inhibitors) — would dramatically shift 5-HTP toward CNS conversion and reduce peripheral side effects. This is how 5-HTP would be used clinically and rigorously. Not realistic for OTC supplement use.
  • l-tyrosine — to offset dopamine-side AAAD competition. Mechanism contested; some functional-medicine practitioners advocate it; pharmacologically the substrates compete.
  • l-theanine, magnesium-glycinate — calming/GABAergic adjuncts; no mechanistic conflict.

Avoid stacking with

  • l-tryptophan — redundant; doubles the serotonergic load without adding regulatory benefit. Pick one. Tryptophan wins for chronic daily use.
  • MAOIs (phenelzine, tranylcypromine, isocarboxazid) — HIGH serotonin syndrome risk. Avoid completely.
  • Selegiline >5 mg/day — loses MAO-B selectivity, becomes effectively MAOI. Avoid 5-HTP at this dose.
  • SSRIs / SNRIs — moderate risk of serotonin syndrome at therapeutic doses; risk scales with 5-HTP dose. Older psych literature did combine them tactically, but this is clinician territory.
  • Tramadol, triptans, dextromethorphan, MDMA, ondansetron (mild) — all add serotonergic load.
  • Dopamine agonists or L-DOPA (Parkinson's drugs) — AAAD substrate competition will reduce dopamine product in the periphery. Specifically problematic in PD patients on L-DOPA without carbidopa.
  • Agomelatine — already a 5-HT2C antagonist + MT1/2 agonist; adding 5-HTP doesn't obviously help and theoretically complicates the receptor profile. Mechanism conflict more than danger.

Neutral / safe co-administration

  • Most non-serotonergic supplements (DHA, citicoline, NAC, PS, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C, creatine).
  • Modafinil — different mechanism, no overlap.
  • Selank, alpha-GPC — neutral.
▸ Drug interactions deep dive
Drug class Concern level Notes
MAOIs HIGH — avoid Real serotonin syndrome risk; higher than with tryptophan because TPH bypass means more efficient 5-HT generation.
SSRIs / SNRIs MODERATE Serotonin syndrome risk; clinician-only territory if combined.
Selegiline ≥5 mg/day MODERATE-HIGH At doses where MAO-B selectivity is lost, treat as MAOI.
Tramadol MODERATE SNRI activity; pause 5-HTP during course.
Triptans LOW-MODERATE Modest concern; PRN is generally OK.
Dextromethorphan (high doses) MODERATE Recreational doses + 5-HTP = real risk.
Linezolid HIGH MAOI activity. Avoid 5-HTP during course.
L-DOPA (without carbidopa) MODERATE AAAD substrate competition reduces dopamine production.
Carbidopa / benserazide (Synergy in PD context) Peripheral AAAD inhibition shifts 5-HTP to CNS — clinical-use combination.
Bupropion (V5 optional) LOW NDRI, minimal serotonergic load. No real risk.
CYP enzymes None clinically relevant Not a CYP substrate or inhibitor.
Contraceptives None No interaction.
▸ Pharmacogenomics

Variants relevant to 5-HTP response (largely overlapping with tryptophan, but interpreted differently):

  • 5-HTTLPR (SLC6A4) — S/S carriers may respond more strongly to any serotonergic precursor; also more susceptible to side effects.
  • TPH2 SNPs (rs4570625, rs4290270, rs7305115) — these affect tryptophan→5-HTP rate. Loss-of-function TPH2 variants are the one scenario where 5-HTP arguably makes more sense than tryptophan, because TPH2 is the bottleneck being bypassed. This is a niche genetic profile.
  • DDC / AAAD SNPs — affect 5-HTP→5-HT decarboxylation efficiency. Variants exist but aren't well-characterized in 23andMe-grade data.
  • MAO-A VNTR — high-activity allele = faster 5-HT breakdown; may need higher dose to feel effect.
  • MTHFR (C677T, A1298C) — affects BH4 regeneration → indirectly affects serotonin synthesis upstream of 5-HTP. Less directly relevant than for tryptophan.
  • 5-HT2B receptor SNPs — theoretically modulate valvulopathy risk; not standard genotyped.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC Doctor's Best 5-HTP 100 mg (60 or 180 caps) ~$10-22 HIGH Tests for Peak X contaminant. Standard reputable pick. iHerb + Amazon.
OTC NOW Foods 5-HTP 100 mg (60 or 120 caps) ~$15-25 HIGH Reputable brand, CoA available. iHerb + Amazon.
OTC Nootropics Depot 5-HTP ~$15-20 / 60 caps HIGH Third-party tested.
OTC Bulk Supplements 5-HTP powder ~$10-15 / 100 g MED-HIGH Cheapest; CoA per batch; powder dosing required.
Avoid Unbranded / no-CoA 5-HTP — LOW Peak X contamination risk is sourcing-dependent. Don't roll dice.

For Dylan: not buying. L-tryptophan (NOW Foods 500 mg via iHerb) is the V5 selection.

▸ Biomarkers to track (deep)

Baseline (before starting, if used)

  • hs-CRP — high inflammation suggests IDO is shunting tryptophan, which is the niche where 5-HTP has a mechanistic argument. But fix inflammation first.
  • 5-HTTLPR genotype, TPH2 SNPs — from 23andMe (June 2026 for Dylan).
  • B6 (PLP) — required cofactor.
  • Plasma 5-HIAA — 5-HT major metabolite. Specialty test.
  • Eosinophil count + CBC — pre-trial baseline for EMS vigilance.

During use

  • Sleep diary (sleep onset, WASO, dream intensity, morning grogginess).
  • Subjective mood/motivation 1-10 weekly — watch for dopamine-depletion drift.
  • GI tolerability log.
  • If used >3 months daily at >150 mg/day: consider echocardiogram to baseline valve function (especially if any other risk factor present).

Post-cycle

  • Mood/motivation should normalize within 2-4 weeks.
▸ Controversies / open debates Live debate

  1. Is the "TPH bypass = feature" framing correct? Pro-5-HTP camp argues that bypassing the rate-limiting step gives reliable serotonin elevation regardless of cofactor status, IDO state, etc. Pro-tryptophan camp (this verdict's position) argues that the regulatory bottleneck is physiological quality control — bypassing it produces serotonin in the wrong tissues at the wrong times. The peripheral-conversion math strongly supports the tryptophan camp: if most of an oral 5-HTP dose becomes peripheral (not central) serotonin, the bypass is mostly converting tryptophan-saving regulation into peripheral side effects.

  2. How real is the chronic valve concern at supplement doses? No human RCT of chronic 5-HTP has measured echocardiographic outcomes. The mechanism (5-HT2B receptor activation by sustained peripheral 5-HT, leading to fibroblast proliferation in valve interstitium) is well-established for fenfluramine, pergolide, ergotamine, and carcinoid syndrome. Whether typical 5-HTP doses (50-300 mg/day) generate enough sustained peripheral 5-HT to cross the threshold is unknown. Conservative read: avoid chronic high-dose use; intermittent low-dose probably negligible risk.

  3. Peak X / EMS — settled or lingering? Modern reputable brands test for Peak X and most products are clean. The risk vector is unbranded / cheap suppliers. This is similar to the post-1989 tryptophan situation: the molecule isn't the problem; the manufacturer is.

  4. Does dopamine depletion really happen at 100-200 mg doses? Mechanism is real (AAAD substrate competition). Magnitude at supplement doses is debated. User reports of "5-HTP poop-out with mood flattening" are consistent. Solid pharmacological evidence at therapeutic doses is sparser. Conservative read: real enough at chronic daily use to factor in.

  5. 5-HTP for depression — is it actually antidepressant? Mixed. The fluoxetine non-inferiority trial (2012) is a single-trial datum. Modern reviews (Maffei 2019) call evidence "suggestive but insufficient." Most modern psychiatry doesn't use 5-HTP — when serotonergic intervention is clinically warranted, SSRIs/SNRIs are vastly better-evidenced.

  6. Is 5-HTP ever the right call? Niche cases:

    • Documented TPH2 loss-of-function variant (rare).
    • Trial of intermittent low-dose for sleep when tryptophan failed.
    • Clinician-supervised use with carbidopa for Parkinson's-related serotonergic deficits (specialty).
    • Otherwise, default to tryptophan.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW (MEDIUM confidence) for Dylan. L-tryptophan dominates on regulatory mechanism, peripheral-side-effect profile, dopamine preservation, and (importantly for Dylan) brain-priority cognitive output. 5-HTP's only meaningful advantage is faster onset, which is modest. The TPH/IDO regulatory bypass is best understood as a bug, not a feature, in the chronic-daily-use context. Would shift to OPTIONAL-ADD (intermittent low-dose only) if (a) Dylan's June 2026 23andMe shows TPH2 loss-of-function variants AND (b) bloodwork shows persistently low-normal 5-HIAA on tryptophan, AND (c) a clinician is supervising the dosing strategy. Would shift to WATCH-LIST if a future trial demonstrates carbidopa-coadministered 5-HTP outperforms tryptophan for mood/sleep with clean cardiac safety data.
▸ Open questions / gaps Open
  1. What's the actual CNS:peripheral conversion ratio at typical oral doses? The "2:90" framing is approximate; rigorous quantification exists in carbidopa-co-administration studies but not in plain-supplement contexts.
  2. Does chronic daily 5-HTP at supplement doses produce measurable echocardiographic changes over years? No data. Mechanism predicts it should at high enough sustained doses.
  3. Real-world incidence of dopamine-depletion symptoms? Anecdotal reports are consistent; clinical quantification is thin.
  4. Is there a 5-HTP responder genotype (TPH2 LOF) that would justify it over tryptophan in specific individuals? Plausible; not yet a clinical standard.
  5. Peak X contaminant — what's the modern incidence in CoA-tested products? Likely very low, but no published systematic survey post-2010.
▸ Sources (full, with our context)
Back to compact view